Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

Similar articles for PubMed (Select 25010502)

1.

Impact of QRS duration on survival benefit with prophylactic implantable cardioverter-defibrillators: a meta-analysis of randomized controlled trials.

Sipahi I, Chaudhry SP, Issa M, Ambati M, Dagdelen S, Fang JC.

J Cardiovasc Med (Hagerstown). 2014 Jul 10. [Epub ahead of print]

PMID:
25010502
2.

Effect of left ventricular ejection fraction and QRS duration on the survival benefit of implantable cardioverter-defibrillators: meta-analysis of primary prevention trials.

Katritsis DG, Siontis KC, Bigger JT, Kadish AH, Steinman R, Zareba W, Siontis GC, Bardy GH, Ioannidis JP.

Heart Rhythm. 2013 Feb;10(2):200-6. doi: 10.1016/j.hrthm.2012.10.039. Epub 2012 Oct 27. Review.

PMID:
23107652
3.

Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2005;5(14):1-74. Epub 2005 Sep 1.

4.

Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials.

Ezekowitz JA, Armstrong PW, McAlister FA.

Ann Intern Med. 2003 Mar 18;138(6):445-52. Review.

PMID:
12639076
5.

Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.

Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S, Machado C.

Arch Intern Med. 2009 Sep 14;169(16):1500-6. doi: 10.1001/archinternmed.2009.255.

PMID:
19752408
6.

The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis.

Stavrakis S, Lazzara R, Thadani U.

J Cardiovasc Electrophysiol. 2012 Feb;23(2):163-8. doi: 10.1111/j.1540-8167.2011.02144.x. Epub 2011 Aug 4.

PMID:
21815961
7.

Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators.

Santangeli P, Di Biase L, Dello Russo A, Casella M, Bartoletti S, Santarelli P, Pelargonio G, Natale A.

Ann Intern Med. 2010 Nov 2;153(9):592-9. doi: 10.7326/0003-4819-153-9-201011020-00009. Review. Erratum in: Ann Intern Med. 2011 Jun 7;154(11):780.

PMID:
21041579
8.

Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis.

Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV.

Circ Arrhythm Electrophysiol. 2014 Feb;7(1):164-70. doi: 10.1161/CIRCEP.113.001217. Epub 2014 Jan 20. Review.

9.

Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction.

Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C, McAlister FA.

Ann Intern Med. 2007 Aug 21;147(4):251-62. Review.

PMID:
17709759
10.
11.

Biventricular pacing (cardiac resynchronization therapy): an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2005;5(13):1-60. Epub 2005 Sep 1.

12.

Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials.

Sipahi I, Carrigan TP, Rowland DY, Stambler BS, Fang JC.

Arch Intern Med. 2011 Sep 12;171(16):1454-62. doi: 10.1001/archinternmed.2011.247. Epub 2011 Jun 13. Erratum in: Arch Intern Med. 2011 Sep 12;171(16):1429.

PMID:
21670335
13.

Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis.

Kong MH, Al-Khatib SM, Sanders GD, Hasselblad V, Peterson ED.

Cardiol J. 2011;18(5):503-14. Review. Erratum in: Cardiol J. 2012;19(4):442.

14.

The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death.

Henyan NN, White CM, Gillespie EL, Smith K, Coleman CI, Kluger J.

J Intern Med. 2006 Nov;260(5):467-73.

PMID:
17040253
15.

The clinical and cost-effectiveness of implantable cardioverter defibrillators: a systematic review.

Bryant J, Brodin H, Loveman E, Payne E, Clegg A.

Health Technol Assess. 2005 Sep;9(36):1-150, iii. Review.

17.

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.

18.

Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction.

Chan PS, Chow T, Kereiakes D, Schloss EJ, Waller T, Eagle K, Hayward RA, Vijan S.

Arch Intern Med. 2006 Nov 13;166(20):2228-33.

PMID:
17101941
19.

Cardiac resynchronization therapy and implantable cardiac defibrillators in left ventricular systolic dysfunction.

McAlister FA, Ezekowitz J, Dryden DM, Hooton N, Vandermeer B, Friesen C, Spooner C, Rowe BH.

Evid Rep Technol Assess (Full Rep). 2007 Jun;(152):1-199. Review.

20.

Fish-oil supplementation in patients with implantable cardioverter defibrillators: a meta-analysis.

Jenkins DJ, Josse AR, Beyene J, Dorian P, Burr ML, LaBelle R, Kendall CW, Cunnane SC.

CMAJ. 2008 Jan 15;178(2):157-64. doi: 10.1503/cmaj.070261. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk